COSMO Pharmaceuticals N.V.
A specialty pharmaceutical firm focused on gastroenterology, dermatology, and healthtech.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Manufacturing
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2026-01-12 01:00 |
Cosmo Enters Scale Up Phase with €104M Revenue, €128M Cash, and Breakout AI and…
|
English | DOC • 14.6 KB | ||
| 2026-01-12 01:00 |
Mit einem Umsatz von EUR 104 Mio., EUR 128 Mio. an Cash sowie bahnbrechenden KI…
|
German | DOC • 17.6 KB | ||
| 2025-12-03 01:00 |
Cosmo announces breakthrough Phase III Topline results from Scalp 1 and Scalp 2…
|
English | HTML • 11.3 KB | ||
| 2025-12-03 01:00 |
Bahnbrechende Phase-III-Topline-Ergebnisse für Clascoterone 5%-Lösung bei männl…
|
German | HTML • 14.1 KB | ||
| 2025-11-14 01:00 |
Winlevi® Receives Regulatory Approval in Brazil – Expanding Global Access to a …
|
English | HTML • 5.3 KB | ||
| 2025-11-14 01:00 |
Winlevi® erhält die behördliche Zulassung in Brasilien – Erweiterung des weltwe…
|
German | HTML • 6.3 KB | ||
| 2025-11-11 01:00 |
Cosmo’s ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability …
|
English | HTML • 5.1 KB | ||
| 2025-11-11 01:00 |
Cosmo erhält höhere ESG-Bewertung von S&P Global, verstärkt Engagement für Nach…
|
German | HTML • 6.2 KB | ||
| 2025-11-04 01:00 |
Cosmo announces Upcoming Investor Events
|
English | HTML • 3.3 KB | ||
| 2025-11-04 01:00 |
Cosmo kündigt bevorstehende Investoren-Veranstaltungen an
|
German | HTML • 3.7 KB | ||
| 2025-11-03 01:00 |
Cosmo Receives CE Certification for ColonPRO EU – The most Advanced AI Software…
|
English | HTML • 6.0 KB | ||
| 2025-11-03 01:00 |
Cosmo erhält CE-Zertifizierung für ColonPRO EU – die fortschrittlichste KI-Soft…
|
German | HTML • 7.3 KB | ||
| 2025-10-21 02:00 |
Cosmo Pharmaceuticals receives regulatory approval by the European Commission f…
|
English | HTML • 6.1 KB | ||
| 2025-10-21 02:00 |
Cosmo Pharmaceuticals erhält nach positiver Stellungnahme des CHMP die behördli…
|
German | HTML • 7.2 KB | ||
| 2025-10-07 02:00 |
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
|
English | HTML • 5.2 KB |
Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for COSMO Pharmaceuticals N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
